NovoCure (NVCR) Stock Forecast: StockMap's 2-Week Call
NVCR stock forecast: StockMap's model leans Underperform on NovoCure for the two weeks after the Nov 13 close, toward NVCR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 3 two-week windows on NVCR since Sep 24; by chance, a call on the same dates was right 51% of the time.
NovoCure last closed at $11.83, +0.94% on the session.
Against the IVW growth benchmark the position is +1.85% over the forecast window.
NovoCure's market cap is $1.38B as of November 13, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -30 (too close to call).
Where NVCR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 2 bullish and 13 bearish.
Agreement across those insights is 87%.
23 daily calls for NVCR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks NovoCure in the 22nd percentile on return on equity, where 100 is best.
NovoCure is classified under Health Care / Health Care Equipment & Supplies.
StockMap tracks NovoCure as the 54th largest of the 142 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.
Across that group the current two-week reads are 74 Neutral, 52 Moderate Underperform, 13 Strong Underperform and 3 Moderate Outperform.
On that composite NovoCure ranks 99th of 142 in the group, against a group median of -0.15.